Regeneron Pharmaceuticals (NASDAQ: REGN) recently received a number of ratings updates from brokerages and research firms:

  • 8/9/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $580.00 price target on the stock, up previously from $573.00.
  • 8/9/2017 – Regeneron Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $540.00 price target on the stock. According to Zacks, “Regeneron’s second-quarter results were impressive as both earnings and sales beat estimates on the back of strong Eylea sales which grabbed additional market share. Regeneron’s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug's label for additional indications. The increase in guidance was also encouraging. The FDA’s approval of Dupixent was a major boost to the company’s portfolio and the company is working to expand its label. A potential approval of the drug in the EU in the second half will further boost sales. Further, the approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the U.S.and EU has boosted the company’s portfolio. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress.”
  • 8/9/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $471.00 price target on the stock, up previously from $418.00.
  • 8/9/2017 – Regeneron Pharmaceuticals had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $455.00 price target on the stock, up previously from $427.00.
  • 8/9/2017 – Regeneron Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $472.00 price target on the stock, up previously from $469.00.
  • 8/8/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Robert W. Baird from a “neutral” rating to an “underperform” rating. They now have a $408.00 price target on the stock. They wrote, “nothing to scoff at,” Skorney said in his downgrade note. However, investor expectations for a strong performance has “stretched the valuation beyond what is reasonable” based on the initial launch metrics (see Skorney’s track record here).In fact, investor expectation shifted from “high” in late April/May to “extraordinary” today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis’ blockbuster therapy, Cosentyx.”We believe shares reflect a greater degree of optimism than is warranted,” Skorney emphasized. “We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408.”
  • 8/4/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $535.00 price target on the stock, up previously from $489.00.
  • 8/4/2017 – Regeneron Pharmaceuticals had its price target raised by analysts at Citigroup Inc from $555.00 to $575.00. They now have a “buy” rating on the stock.
  • 8/3/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 8/3/2017 – Regeneron Pharmaceuticals was given a new $491.00 price target on by analysts at BMO Capital Markets. They now have a “hold” rating on the stock.
  • 8/3/2017 – Regeneron Pharmaceuticals was given a new $522.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 8/1/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Robert W. Baird from a “neutral” rating to an “underperform” rating. They now have a $408.00 price target on the stock. They wrote, “nothing to scoff at,” Skorney said in his downgrade note. However, investor expectations for a strong performance has “stretched the valuation beyond what is reasonable” based on the initial launch metrics (see Skorney’s track record here).In fact, investor expectation shifted from “high” in late April/May to “extraordinary” today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis’ blockbuster therapy, Cosentyx.”We believe shares reflect a greater degree of optimism than is warranted,” Skorney emphasized. “We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408.”
  • 8/1/2017 – Regeneron Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $557.00 price target on the stock.
  • 7/31/2017 – Regeneron Pharmaceuticals had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $484.00 price target on the stock.
  • 7/28/2017 – Regeneron Pharmaceuticals was given a new $522.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/22/2017 – Regeneron Pharmaceuticals had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $450.00 price target on the stock, up previously from $400.00.
  • 7/21/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Bank of America Corporation. They now have a $593.00 price target on the stock, up previously from $589.00.
  • 7/21/2017 – Regeneron Pharmaceuticals had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $484.00 price target on the stock, up previously from $421.00.
  • 7/14/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Credit Suisse Group to a “hold” rating. They now have a $485.00 price target on the stock.
  • 7/10/2017 – Regeneron Pharmaceuticals had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $450.00 price target on the stock, up previously from $405.00.
  • 7/6/2017 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/4/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Regeneron’s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug's label for additional indications. The FDA’s approval of Dupixent was a major boost to the company’s portfolio and Regeneron is evaluating the drug for additional indications like asthma. The approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the U.S.and EU will further diversify the company’s portfolio. On the other hand, although sales of Praluent have failed to impress due to the present payer utilization management restrictions in the U.S. and limited market access in Europe, the drug is expected to have blockbuster potential. Shares of the company have also outperformed the industry in the year so far.”
  • 6/30/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $540.00 price target on the stock, up previously from $480.00.
  • 6/28/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $573.00 price target on the stock, up previously from $493.00.
  • 6/26/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating. They now have a $480.00 price target on the stock, up previously from $410.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 6/24/2017 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 6/22/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $573.00 price target on the stock.
  • 6/22/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $547.00 price target on the stock, up previously from $475.00.
  • 6/21/2017 – Regeneron Pharmaceuticals had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $421.00 price target on the stock.
  • 6/20/2017 – Regeneron Pharmaceuticals had its price target raised by analysts at Piper Jaffray Companies from $446.00 to $557.00. They now have an “overweight” rating on the stock.
  • 6/20/2017 – Regeneron Pharmaceuticals was given a new $484.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 6/14/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 6/13/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $493.00 price target on the stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 460.08 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The stock has a market cap of $48.78 billion, a price-to-earnings ratio of 46.16 and a beta of 1.66. The stock’s 50 day moving average is $497.25 and its 200 day moving average is $425.70.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. The company’s revenue was up 21.2% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.84 EPS for the current fiscal year.

In related news, SVP Michael S. Aberman sold 2,269 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the completion of the sale, the senior vice president now owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Robert E. Landry sold 526 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total value of $248,371.94. Following the sale, the senior vice president now directly owns 9,099 shares of the company’s stock, valued at approximately $4,296,456.81. The disclosure for this sale can be found here. Insiders have sold 56,922 shares of company stock valued at $27,383,105 in the last ninety days. Corporate insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.